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Case report
  A 40-year-old female patient with recently diagnosed 
non-small-cell lung cancer (NSCLC) was referred to our 
department for diagnosis and therapeutic intervention due 
to acute superior vena cava (SVC) syndrome symptoms. 
The patient had facial and superior limbic swelling and 
extensive superficial venous collaterals. Contrast-enhanced 
computed tomography (CT) scan demonstrated enlarged 
superior mediastinal lymph nodes compressing and ob-
structing both brachiocephalic veins and the distal segment 
of  the SVC. The acute onset of  symptoms raised a strong 
suspicion of  acute thrombosis, and the patient was brought 
to the angiography department for a venogram and (if  
possible) for interventional recanalization of  the obstructed 
vessels.
Access was gained via a 5F-size sheath in the right com-
mon femoral vein, as preinterventional  Doppler examina-
tion of  all the possible access sites unmasked the presence 
of  an obstructive thrombus in the right internal jugular 
vein and a narrow lumen of  the right brachial vein. Ini-
tially, a 0.035-inch hydrophilic guidewire (Radiofo-
cus,Terumo, Somerset, NJ) was used for catheterization of  
the right brachiocephalic vein, but the occlusion was resis-
tant to guidewire passage. Then, the guidewire was ad-
vanced to the left brachiocephalic vein and, after selective 
catheterization, the venogram through a vertebral catheter 
revealed total occlusion of  the SVC at the level of  the 
brachiocephalic veins confluence and the presence of  a 
large acute thrombus in left brachiocephalic vein 
(Figs. 1A, B).
Due to the patient’s acute onset of  symptoms and her 
deteriorating clinical condition, it was decided (after con-
sulting with her attending physician) to immediately reca-
nalize the left brachiocephalic vein and SVC by applying 
the Angiojet device, and then to place a stent. A supple-
mentary informed consent was taken, and the patient was 
constantly monitored.
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The introductory 5Fr sheath was replaced with a 6 Fr -40 
cm long Arrow sheath, and the thrombus was crossed using 
an hydrophilic 0.035-inch guide wire (Radiofocus;Terumo, 
Somerset, NJ). The hydrophilic guidewire was then ex-
changed for a stiff  guidewire (Amplatz Super Stiff  0,035-
inch), and a 6 Fr rheolytic thrombectomy catheter was 
placed within the thrombus. After three passes of  the An-
giojet catheter through the whole length of  the left brachio-
cephalic vein and peripheral SVC, the procedure was ter-
minated because significant reduction in thrombus burden 
was observed angiographically. A postprocedure, repeat 
venogram revealed a partial recanalization of  the two ves-
sels (Fig. 2).
The patient’s cardiac rhythm was monitored, as cardiac 
arrhythmias may occur during catheter use. The patient 
complained about a continuous sharp chest pain during 
every implementation of  the thrombectomy rheolytic sys-
tem, which was not followed by ECG changes and was 
relieved with the deactivation of  the device.
Finally, a self-expanding stent (14mm-60mm Bard E-
Luminex Vascular stent) was placed in the vessel lumen, 
followed by balloon dilation (Figs. 3A, B).
The final venogram revealed a satisfactory patency of  
the SVC and left brachiocephalic vein, and no treatment 
complications were noted. The neck and arm swelling de-
creased, as well as the self-reported shortness of  breath, 
which was relieved within a few minutes after the end of  
the procedure. The patient was hospitalized for continuing 
heparin therapy (to ensure stent patency), and was then 
discharged.
At 3-month followup, 
the patient was still 
asymptomatic, and the 
followup CT scan 
confirmed a patent left 
brachiocephalic vein 
and SVC with the 
stent in place, without 
any complications 
(Figs. 4A, B). 
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Figure 2. After rheolytic thrombectomy, the venogram re-
vealed a partial recanalization of the left brachiocephalic 
vein and peripheral superior vena cava.
Figure 1. A. Superior vena cava venogram revealing the 
presence of thrombus at the more distal part of SVC at the 
level of brachiocephalic veins confluence (arrow). B. After 
selective catheterization of the left brachiocephalic vein, a 
large thrombus was revealed (arrow).
Figure 3. A. A stent (arrow) was deployed in the left 
brachiocephalic vein. B Venogram after stent deployment 
(arrow).
Figure 4. At 3-month 
followup CT with intra-
venous contrast me-
dia, a patent left 
brachiocephalic vein 
(A, arrow) as well as 
superior vena cava 
and the stent in place 
(B, arrow) were im-
aged.
Discussion
 SVC and brachiocephalic vein thrombosis, especially 
SVC, occurs when a mechanical obstruction occludes the 
SVC. Obstruction may either be the result of  extraluminal 
compression by a tumor or enlarged lymph nodes (1), or 
intraluminal obstruction by thrombosis or tumor. Acute 
and complete obstruction of  the SVC is caused more often 
by thrombosis than by compression or infiltration by a tu-
mor (2). Risk factors for the formation of  thrombus in the 
SVC include a hypercoagulable state in patients with ma-
lignancy, damage to the intima of  the SVC from central 
venous catheters, and venous stasis from extraluminal com-
pression (3, 4). The most common causes are bronchogenic 
carcinoma (small-cell lung cancer and [less frequently] 
NSCLC) (5) and lymphoma. In the present era, benign 
causes account for 20-40% of  cases of  SVC syndrome.
Symptoms may include cough; dyspnea; orthopnea; 
dysphagia; swelling of  the face, neck and upper extremities;  
and severe headache, as well as distension of  the superficial 
collateral veins in the chest wall (6). When venous circula-
tion through the SVC is impaired, venous hypertension, 
venous stasis, and decreased cardiac output may ensue. If  
untreated, these symptoms progress to laryngeal and cere-
bral edema, stupor, coma, pulmonary complications, and 
death. Contrast-enhanced CT is the preferred diagnostic 
modality (5).
Traditionally, the treatment of  choice for patients with 
mediastinal vein obstruction is radiotherapy, chemotherapy, 
or surgery (7). In order to acutely restore vascular flow and 
palliate symptoms, mechanical or pharmaceutical throm-
bolysis and endoluminal stenting may be performed. In our 
case, there was a successful clinical outcome with the com-
bined use of  rheolytic thrombectomy and stent placement 
in one treatment session. A variety of  therapeutic strategies 
may be employed in the individualized clinical setting, in 
the absence of  large-scale trials comparing therapeutic 
alternatives.
Available therapies include medical therapy (anticoagula-
tion, corticosteroids), venous bypass, chemotherapy, exter-
nal beam irradiation, and endovascular therapy. Evidence-
based guidelines for management of  SVC thrombosis in 
malignancy, according to National Comprehensive Cancer 
Network (NCCN) guidelines version 2012.1, support anti-
coagulation therapy and pharmacomechanical thromboly-
sis. Endovascular stenting is a safe and effective, minimally 
invasive technique for acute symptom relief  of  SVC ob-
struction and is preferred, as the average survival of  pa-
tients with malignancy complicated by SVC syndrome is 6 
months. Stenting usually provides instant relief  of  symp-
toms and, as it does not interfere with chemotherapy and 
radiotherapy, they can be combined. The main indication 
for stent placement is symptomatic malignant SVC obstruc-
tion, either at initial presentation or after failed chemother-
apy or radiotherapy (8). There are no absolute contraindi-
cations to stent placement. Relative contraindications are 
malignancies with a very good chance of  cure or remission. 
In addition, stenting should be avoided if  at all possible in 
benign disease, because patients have long life expectancies 
and occlusion of  the stent would be expected during long-
term followup (8). Success rates range between 95% and 
100%, and 1-year primary patency rates are between 64% 
and 76% (9). Symptoms may recur, usually as a result of  
thrombotic occlusion of  the stent (reocclusion due to 
thrombosis or tumor in-growth was only 11%, as compared 
to 17% to 19% with radiation or chemotherapy). This can 
be treated with thrombolysis or further coaxial stent 
placement. 
Thrombectomy or thrombolysis is often attempted be-
fore stent deployment, when stent placement is difficult or 
dangerous due to the presence of  a large amount of  
thrombus. In one series, technical success of  transcatheter 
thrombolysis and stent placement was 95%, with primary 
clinical patency of  79% in patients with underlying malig-
nancy (10). However, catheter-directed thrombolysis before 
stent placement is usually time-consuming (12 to 48 hours), 
and with a high procedural risk for the patient. More spe-
cifically, there is a greater risk of  hematoma, gastrointesti-
nal bleeding, epistaxis, hemoptysis, and stent insertion 
morbidity. In order to avoid the adverse effects of  pharma-
ceutical thrombolysis, we chose to perform percutaneous 
mechanical thrombectomy 
Rheolytic thrombectomy is a type of  mechanical throm-
bectomy that has been used to remove thrombus in coro-
nary arteries, saphenous vein grafts, and peripheral veins 
and arteries, and in clotted dialysis fistula grafts plus cases 
of  dural sinus thrombosis, with good results. It has been 
also used successfully to treat both pulmonary embolism 
(11) and deep-vein thrombosis. The literature provides only 
case reports of  combined pharmacomechanical throm-
bolysis in SVC thrombosis, and not a single case of  rhe-
olytic thrombectomy (12).
The rheolytic thrombectomy catheter’s function is based 
on the principle of  Bernoulli. High-speed saline jets 
through a small-caliber tip create a negative pressure zone, 
causing a vacuum effect. The thrombus is pulled from the 
vessel and is fragmented into particles smaller than eryth-
rocytes. These particles are then evacuated through the 
body of  the catheter and collected into a collecting bag. 
Several sizes of  rheolytic thrombectomy catheters can be 
used, including 4F 135-cm (used mainly for coronary inter-
vention), 5F 140-cm, and 6F 120-cm (used mainly for pe-
ripheral vascular intervention) that are designed to go over 
a 0.014-inch guidewire. The maximum volume recom-
mended to be aspirated is approximately 200–600 mL, 
depending on the catheter diameter and on whether the 
treated vessel is occluded or not (13).  
The rheolytic thrombectomy catheter system has the 
advantage of  being able to clear a vessel with a much 
larger diameter than the catheter diameter, compared to 
other mechanical devices. In addition, a shorter revascu-
larization time is needed, which may reduce complications 
such as hemorrhage or distal embolization of  a clot. Even 
in cases of  combined pharmacorheolytic thrombolysis, this 
system can reduce the amount of  thrombolytic agent ad-
ministered, thereby reducing the risk of  hemorrhagic con-
version, which is one important advantage (14). 
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The usual observed complication is transient hemolysis. 
Although hemolysis is usually well tolerated, it can rarely 
cause arrhythmias. Other complications of  rheolytic 
thrombectomy, which are rare in experienced operators, 
include wound hematoma and infection, a reperfusion syn-
drome with hemorrhage, and distal embolization. Addi-
tionally, the cost of  the pump-drive set and the risk of  fluid 
overload are important factors to take into consideration. 
Due to procedure-related complications and deaths (most 
commonly hemoptysis), FDA has issued a black-box warn-
ing for the Angiojet device (15). 
In conclusion, SVC and brachiocephalic vein thrombosis,  
clinically presented as SVC syndrome, is an everyday com-
plication in patients with lung cancer. Treatment options 
include thrombolysis or thrombectomy with stent place-
ment along with radiotherapy and chemotherapy.
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